Evidence map›Paper›PMID 33614032›Full record

ArticleClinical & translational immunology2021

High levels of soluble CD25 in COVID-19 severity suggest a divergence between anti-viral and pro-inflammatory T-cell responses.

Min Xie, Joseph Yunis, Yin Yao, Jing Shi, Yang Yang, Pengcheng Zhou, Kaili Liang, Yanmin Wan, Ahmed Mehdi, Zhian Chen and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 3 countries.

Min XieDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Joseph YunisThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.
Yin YaoThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.
Jing ShiDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Yang YangThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.
Pengcheng ZhouThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.ORCID https://orcid.org/0000-0002-7736-2902
Kaili LiangChina-Australia Centre for Personalised Immunology Shanghai Renji Hospital Shanghai Jiaotong University School of Medicine Shanghai.
Yanmin WanDepartment of Infectious Diseases Huashan Hospital Fudan University Shanghai China.
Ahmed MehdiThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.
Zhian ChenThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.
Naiqi WangThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.
Shuyun XuDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Min ZhouDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Muqing YuDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Ke WangDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Yu TaoDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Ying ZhouDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Xiaochen LiDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Xiansheng LiuDepartment of Respiratory and Critical Care Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Xiao YuDepartment of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Yunbo WeiShandong Artificial Intelligence Institute Qilu University of Technology (Shandong Academy of Sciences) Jinan China.
Zheng LiuDepartment of Otolaryngology-Head and Neck Surgery Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Jonathan SprentImmunology Division Garvan Institute of Medical Research Darlinghurst NSW Australia.
Di YuThe University of Queensland Diamantina Institute Faculty of Medicine The University of Queensland Brisbane QLD Australia.ORCID https://orcid.org/0000-0003-1721-8922
National Health and Family Planning Commission · CNThe University of Queensland · AUAustralian National University · AUQilu University of Technology · CNTongji Hospital · CNFudan University · CNGarvan Institute of Medical Research · AURenji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe aimed to gain an understanding of the paradox of the immunity in COVID-19 patients with T cells showing both functional defects and hyperactivation and enhanced proliferation.

methodsA total of 280 hospitalised patients with COVID-19 were evaluated for cytokine profiles and clinical features including viral shedding. A mouse model of acute infection by lymphocytic choriomeningitis virus (LCMV) was applied to dissect the relationship between immunological, virological and pathological features. The results from the mouse model were validated by published data set of single-cell RNA sequencing (scRNA-seq) of immune cells in bronchoalveolar lavage fluid (BALF) of COVID-19 patients.

resultsThe levels of soluble CD25 (sCD25), IL-6, IL-8, IL-10 and TNF-α were higher in severe COVID-19 patients than non-severe cases, but only sCD25 was identified as an independent risk factor for disease severity by multivariable binary logistic regression analysis and showed a positive association with the duration of viral shedding. In agreement with the clinical observation, LCMV-infected mice with high levels of sCD25 demonstrated insufficient anti-viral response and delayed viral clearance. The elevation of sCD25 in mice was mainly contributed by the expansion of CD25

conclusionThese results suggest that high levels of sCD25 in COVID-19 patients probably result from insufficient anti-viral immunity and indicate an expansion of pro-inflammatory T cells that contribute to disease severity.

Indexed as

CD25+PD‐1+ CD8+ T cellCOVID‐19 patientsdisease severitySARS‐CoV‐2soluble CD25

Identifiers

PMID33614032
PMCPMC7883478
OpenAlexW3133282616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.